vs
亚什兰（ASH）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是Pacira BioSciences, Inc.的2.2倍（$386.0M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs -3.1%，领先4.8%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -4.7%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
ASH vs PCRX — 直观对比
营收规模更大
ASH
是对方的2.2倍
$177.4M
营收增速更快
PCRX
高出9.7%
-4.7%
净利率更高
PCRX
高出4.8%
-3.1%
两年增速更快
PCRX
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $177.4M |
| 净利润 | $-12.0M | $2.9M |
| 毛利率 | 27.2% | — |
| 营业利润率 | -1.6% | 3.9% |
| 净利率 | -3.1% | 1.6% |
| 营收同比 | -4.7% | 5.0% |
| 净利润同比 | 92.7% | — |
| 每股收益（稀释后） | $-0.26 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $386.0M | $196.9M | ||
| Q3 25 | $477.0M | $179.5M | ||
| Q2 25 | $463.0M | $181.1M | ||
| Q1 25 | $479.0M | $168.9M | ||
| Q4 24 | $405.0M | $187.3M | ||
| Q3 24 | $521.0M | $168.6M | ||
| Q2 24 | $544.0M | $178.0M |
净利润ASHPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-12.0M | — | ||
| Q3 25 | $31.0M | $5.4M | ||
| Q2 25 | $-742.0M | $-4.8M | ||
| Q1 25 | $31.0M | $4.8M | ||
| Q4 24 | $-165.0M | — | ||
| Q3 24 | $17.0M | $-143.5M | ||
| Q2 24 | $6.0M | $18.9M |
毛利率ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | 27.2% | 79.5% | ||
| Q3 25 | 33.3% | 80.9% | ||
| Q2 25 | 28.5% | 77.4% | ||
| Q1 25 | 30.7% | 79.7% | ||
| Q4 24 | 27.4% | 78.7% | ||
| Q3 24 | 33.2% | 76.9% | ||
| Q2 24 | 34.2% | 75.1% |
营业利润率ASHPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | -1.6% | 1.2% | ||
| Q3 25 | 12.8% | 3.5% | ||
| Q2 25 | -152.9% | 4.7% | ||
| Q1 25 | 10.6% | 1.2% | ||
| Q4 24 | -44.2% | 13.2% | ||
| Q3 24 | 6.1% | -82.8% | ||
| Q2 24 | -11.2% | 15.9% |
净利率ASHPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | -3.1% | — | ||
| Q3 25 | 6.5% | 3.0% | ||
| Q2 25 | -160.3% | -2.7% | ||
| Q1 25 | 6.5% | 2.8% | ||
| Q4 24 | -40.7% | — | ||
| Q3 24 | 3.3% | -85.1% | ||
| Q2 24 | 1.1% | 10.6% |
每股收益（稀释后）ASHPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.26 | $0.05 | ||
| Q3 25 | $0.83 | $0.12 | ||
| Q2 25 | $-16.21 | $-0.11 | ||
| Q1 25 | $0.65 | $0.10 | ||
| Q4 24 | $-3.50 | $0.38 | ||
| Q3 24 | $0.34 | $-3.11 | ||
| Q2 24 | $0.12 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $144.3M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $653.9M |
| 总资产 | $4.5B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $304.0M | $238.4M | ||
| Q3 25 | $215.0M | $246.3M | ||
| Q2 25 | $207.0M | $445.9M | ||
| Q1 25 | $168.0M | $493.6M | ||
| Q4 24 | $219.0M | $484.6M | ||
| Q3 24 | $300.0M | $453.8M | ||
| Q2 24 | $399.0M | $404.2M |
总债务ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $372.2M | ||
| Q3 25 | $1.4B | $376.7M | ||
| Q2 25 | $1.4B | $580.5M | ||
| Q1 25 | $1.3B | $583.4M | ||
| Q4 24 | $1.3B | $585.3M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
股东权益ASHPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.9B | $693.1M | ||
| Q3 25 | $1.9B | $727.2M | ||
| Q2 25 | $1.9B | $757.8M | ||
| Q1 25 | $2.6B | $798.5M | ||
| Q4 24 | $2.6B | $778.3M | ||
| Q3 24 | $2.9B | $749.6M | ||
| Q2 24 | $3.0B | $879.3M |
总资产ASHPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.5B | $1.3B | ||
| Q3 25 | $4.6B | $1.3B | ||
| Q2 25 | $4.6B | $1.5B | ||
| Q1 25 | $5.2B | $1.6B | ||
| Q4 24 | $5.2B | $1.6B | ||
| Q3 24 | $5.6B | $1.5B | ||
| Q2 24 | $5.7B | $1.6B |
负债/权益比ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | 0.54× | ||
| Q3 25 | 0.73× | 0.52× | ||
| Q2 25 | 0.73× | 0.77× | ||
| Q1 25 | 0.52× | 0.73× | ||
| Q4 24 | 0.51× | 0.75× | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | — |
| 自由现金流经营现金流 - 资本支出 | $111.0M | — |
| 自由现金流率自由现金流/营收 | 28.8% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | — |
8季度趋势，按日历期对齐
经营现金流ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | $125.0M | $43.7M | ||
| Q3 25 | $40.0M | $60.8M | ||
| Q2 25 | $115.0M | $12.0M | ||
| Q1 25 | $9.0M | $35.5M | ||
| Q4 24 | $-30.0M | $33.1M | ||
| Q3 24 | $80.0M | $53.9M | ||
| Q2 24 | $127.0M | $53.2M |
自由现金流ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | $111.0M | $43.5M | ||
| Q3 25 | $6.0M | $57.0M | ||
| Q2 25 | $95.0M | $9.3M | ||
| Q1 25 | $-12.0M | $26.9M | ||
| Q4 24 | $-53.0M | $31.0M | ||
| Q3 24 | $42.0M | $49.8M | ||
| Q2 24 | $98.0M | $51.6M |
自由现金流率ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | 28.8% | 22.1% | ||
| Q3 25 | 1.3% | 31.7% | ||
| Q2 25 | 20.5% | 5.1% | ||
| Q1 25 | -2.5% | 15.9% | ||
| Q4 24 | -13.1% | 16.6% | ||
| Q3 24 | 8.1% | 29.6% | ||
| Q2 24 | 18.0% | 29.0% |
资本支出强度ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.1% | ||
| Q3 25 | 7.1% | 2.2% | ||
| Q2 25 | 4.3% | 1.5% | ||
| Q1 25 | 4.4% | 5.1% | ||
| Q4 24 | 5.7% | 1.1% | ||
| Q3 24 | 7.3% | 2.4% | ||
| Q2 24 | 5.3% | 0.9% |
现金转化率ASHPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
